CLEC12A and chronic myelogenous leukemia, BCR-ABL1 positive: We also confirmed target-specific killing, as there was no cytotoxicity against CLL-1-negative K562 chronic myeloid leukemia cells (Supplementary Fig. 6C) or A-375 melanoma cells (Supplementary Fig. 6D).